• Something wrong with this record ?

A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC

P. Gascón, R. Nagarkar, M. Šmakal, KN. Syrigos, CH. Barrios, JC. Sánchez, L. Zhang, DH. Henry, D. Gordon, V. Hirsh, K. Kubota, S. Orlov, G. Thomas, T. Steinmetz, JH. Kang, DK. Tomita, AN. Fleishman, JK. Park, C. De Oliveira Brandao

. 2020 ; 15 (2) : 190-202. [pub] 20191016

Language English Country United States

Document type Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21012891

INTRODUCTION: This study evaluated noninferiority of darbepoetin alfa versus placebo for overall survival (OS) and progression-free survival (PFS) in anemic patients with NSCLC treated to a 12.0-g/dL hemoglobin (Hb) ceiling. METHODS: Adults with stage IV NSCLC expected to receive two or more cycles of myelosuppressive chemotherapy and Hb less than or equal to 11.0 g/dL were randomized 2:1 to blinded 500 μg darbepoetin alfa or placebo every 3 weeks. The primary endpoint was OS; a stratified Cox proportional hazards model was used to evaluate noninferiority (upper confidence limit for hazard ratio [HR] < 1.15). Secondary endpoints were PFS and incidence of transfusions or Hb less than or equal to 8.0 g/dL from week 5 to end of the efficacy treatment period. RESULTS: The primary analysis set included 2516 patients: 1680 were randomized to darbepoetin alfa; 836 to placebo. The study was stopped early per independent Data Monitoring Committee recommendation after the primary endpoint was met with no new safety concerns. Darbepoetin alfa was noninferior to placebo for OS (stratified HR = 0.92; 95% confidence interval [CI]: 0.83‒1.01) and PFS (stratified HR = 0.95; 95% CI: 0.87‒1.04). Darbepoetin alfa was superior to placebo for transfusion or Hb less than or equal to 8.0 g/dL from week 5 to end of the efficacy treatment period (stratified odds ratio = 0.70; 95% CI: 0.57‒0.86; p < 0.001). Objective tumor response was similar between the groups (darbepoetin alfa, 36.4%; placebo, 32.6%). Incidence of serious adverse events was 31.1% in both groups. No unexpected adverse events were observed. CONCLUSIONS: Darbepoetin alfa dosed to a 12.0-g/dL Hb ceiling was noninferior to placebo for OS and PFS and significantly reduced odds of transfusion or Hb less than or equal to 8.0 g/dL in anemic patients with NSCLC receiving myelosuppressive chemotherapy.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012891
003      
CZ-PrNML
005      
20210507103347.0
007      
ta
008      
210420s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jtho.2019.10.005 $2 doi
035    __
$a (PubMed)31629060
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Gascón, Pere $u Department of Hematology-Oncology, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain. Electronic address: gascon@clinic.cat
245    12
$a A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC / $c P. Gascón, R. Nagarkar, M. Šmakal, KN. Syrigos, CH. Barrios, JC. Sánchez, L. Zhang, DH. Henry, D. Gordon, V. Hirsh, K. Kubota, S. Orlov, G. Thomas, T. Steinmetz, JH. Kang, DK. Tomita, AN. Fleishman, JK. Park, C. De Oliveira Brandao
520    9_
$a INTRODUCTION: This study evaluated noninferiority of darbepoetin alfa versus placebo for overall survival (OS) and progression-free survival (PFS) in anemic patients with NSCLC treated to a 12.0-g/dL hemoglobin (Hb) ceiling. METHODS: Adults with stage IV NSCLC expected to receive two or more cycles of myelosuppressive chemotherapy and Hb less than or equal to 11.0 g/dL were randomized 2:1 to blinded 500 μg darbepoetin alfa or placebo every 3 weeks. The primary endpoint was OS; a stratified Cox proportional hazards model was used to evaluate noninferiority (upper confidence limit for hazard ratio [HR] < 1.15). Secondary endpoints were PFS and incidence of transfusions or Hb less than or equal to 8.0 g/dL from week 5 to end of the efficacy treatment period. RESULTS: The primary analysis set included 2516 patients: 1680 were randomized to darbepoetin alfa; 836 to placebo. The study was stopped early per independent Data Monitoring Committee recommendation after the primary endpoint was met with no new safety concerns. Darbepoetin alfa was noninferior to placebo for OS (stratified HR = 0.92; 95% confidence interval [CI]: 0.83‒1.01) and PFS (stratified HR = 0.95; 95% CI: 0.87‒1.04). Darbepoetin alfa was superior to placebo for transfusion or Hb less than or equal to 8.0 g/dL from week 5 to end of the efficacy treatment period (stratified odds ratio = 0.70; 95% CI: 0.57‒0.86; p < 0.001). Objective tumor response was similar between the groups (darbepoetin alfa, 36.4%; placebo, 32.6%). Incidence of serious adverse events was 31.1% in both groups. No unexpected adverse events were observed. CONCLUSIONS: Darbepoetin alfa dosed to a 12.0-g/dL Hb ceiling was noninferior to placebo for OS and PFS and significantly reduced odds of transfusion or Hb less than or equal to 8.0 g/dL in anemic patients with NSCLC receiving myelosuppressive chemotherapy.
650    _2
$a dospělí $7 D000328
650    12
$a anemie $x chemicky indukované $x farmakoterapie $7 D000740
650    12
$a protinádorové látky $x terapeutické užití $7 D000970
650    _2
$a darbepoetin alfa $x terapeutické užití $7 D000068256
650    _2
$a dvojitá slepá metoda $7 D004311
650    12
$a erythropoetin $x terapeutické užití $7 D004921
650    _2
$a hemoglobiny $7 D006454
650    _2
$a lidé $7 D006801
650    12
$a nádory plic $x farmakoterapie $7 D008175
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Nagarkar, Rajnish $u Curie Manavata Cancer Center, Nashik, India
700    1_
$a Šmakal, Martin $u Nemocnice Hořovice, NH Hospital a.s., Hořovice, Czech Republic
700    1_
$a Syrigos, Konstantinos N $u Third Department of Medicine, Athens Medical School, Athens, Greece
700    1_
$a Barrios, Carlos H $u Centro de Pesquisa em Oncologia, PUCRS, Porto Alegre, Brazil
700    1_
$a Sánchez, Jesús Cárdenas $u Centro Medico de Colima, Colima, Mexico
700    1_
$a Zhang, Li $u Sun Yat-Sen University Cancer Center, East Guangzhou, China
700    1_
$a Henry, David H $u University of Pennsylvania, Philadelphia, Pennsylvania
700    1_
$a Gordon, David $u Cancer Care Centers of South Texas and US Oncology Research Network, San Antonio, Texas
700    1_
$a Hirsh, Vera $u MUHC Royal Victoria Hospital, Montreal, Quebec, Canada
700    1_
$a Kubota, Kaoru $u Nippon Medical School, Tokyo, Japan
700    1_
$a Orlov, Sergey $u Saint Petersburg State Medical University, Saint Petersburg, Russian Federation
700    1_
$a Thomas, Gary $u South Carolina Cancer Specialists, Hilton Head Island, South Carolina
700    1_
$a Steinmetz, Tilman $u Gemeinschaftspraxis für Hämatologie und Onkologie, Köln, Germany
700    1_
$a Kang, Jin-Hyoung $u The Catholic University of Korea, Seoul, South Korea
700    1_
$a Tomita, Dianne K $u Amgen Inc., Thousand Oaks, California
700    1_
$a Fleishman, Alexander N $u Amgen Inc., Thousand Oaks, California
700    1_
$a Park, Joseph K $u Amgen Inc., Thousand Oaks, California
700    1_
$a De Oliveira Brandao, Cisio $u Amgen Inc., Thousand Oaks, California
773    0_
$w MED00186087 $t Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer $x 1556-1380 $g Roč. 15, č. 2 (2020), s. 190-202
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31629060 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210507103346 $b ABA008
999    __
$a ok $b bmc $g 1651131 $s 1133270
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 15 $c 2 $d 190-202 $e 20191016 $i 1556-1380 $m Journal of thoracic oncology $n J Thorac Oncol $x MED00186087
LZP    __
$a Pubmed-20210420

Find record

Citation metrics

Archiving options